Definium Therapeutics (DFTX) Other Non-Current Assets (2022 - 2026)
Definium Therapeutics (DFTX) reported Other Non-Current Assets of $812000.0 for Q1 2026, up 33.99% year-over-year from $606000.0 in Q1 2025, and down 5.8% on a QoQ basis from $862000.0 in Q4 2025.
Definium Therapeutics (DFTX) has 5 years of Other Non-Current Assets data on file, last reported at $812000.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 33.99% year-over-year to $812000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $812000.0 (up 33.99% YoY) and the FY2025 annual result came in at $862000.0, up 40.62% from the prior year.
- Other Non-Current Assets slipped to $812000.0 in Q1 2026 per DFTX's latest filing, from $862000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.2 million in Q2 2025 and bottomed at $144000.0 in Q1 2024.
- The 5-year median for Other Non-Current Assets is $513500.0 (2024), against an average of $552857.1.
- The widest annual swing landed in 2024, when Other Non-Current Assets tumbled 52.0%; it then soared 320.83% in 2025.
- Tracing DFTX's Other Non-Current Assets over 5 years: stood at $331000.0 in 2022, then slumped by 32.33% to $224000.0 in 2023, then surged by 173.66% to $613000.0 in 2024, then jumped by 40.62% to $862000.0 in 2025, then slipped by 5.8% to $812000.0 in 2026.
- Per Business Quant, the three latest DFTX Other Non-Current Assets figures stand at $812000.0 (Q1 2026), $862000.0 (Q4 2025), and $1.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | 812,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 812,000.00 |
| Dec 31, 2025 | 862,000.00 |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 606,000.00 |
| Dec 31, 2024 | 613,000.00 |
| Sep 30, 2024 | 493,000.00 |
| Jun 30, 2024 | 534,000.00 |
| Mar 31, 2024 | 144,000.00 |
| Dec 31, 2023 | 224,000.00 |
| Sep 30, 2023 | 229,000.00 |
| Jun 30, 2023 | 268,000.00 |
| Mar 31, 2023 | 300,000.00 |
| Dec 31, 2022 | 331,000.00 |